Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A randomized placebo-controlled study in patients with neurogenic bladder dysfunction and recurrent urinary tract infections (UTIs)

Summary

Due to the damage caused to the spinal cord, patients with spinal cord injury, cauda equina syndrome, multiple sclerosis and transverse myelitis may encounter loss of bladder function, which in turn can lead to a debilitating and costly complication: Urinary Tract Infections (UTIs).  

There is strong evidence on the effectiveness of antibiotics as treatment for symptomatic UTIs. Although strong evidence of its effectiveness is lacking, antibiotics have also been widely used for prevention of recurrent UTIs in patients with loss of bladder function. Antimicrobial resistance (AMR) has now become a world-wide health concern and policy makers recently stressed the importance of research into alternative preventative treatments.

The use of immunotherapy is another approach, which works by using certain parts of a persons immune system to fight infections. One immunotherapy option is Uro-Vaxom® oral capsule which consists of which consists of bacterial lysates that work as Pathogen-associated molecular patterns (PAMPs). Previous studies show that Uro-Vaxom® resulted in a significant reduction of UTIs in otherwise healthy patients, as well as being well tolerated.

The PReSUTINeB investigators will investigate if Uro Vaxom can reduce the incidence of symptomatic UTIs in 48 participants in two centres in the UK (Stoke Mandeville Hospital, Buckinghamshire and Oxford Centre for Enablement). The investigators will also look at the signs and symptoms experienced when a participant experiences during a symptomatic UTI.  

 

Study details

Sponsor: Buckinghamshire Healthcare NHS Trust

Funder: National Institute Health Research

Chief Investigator: Mr Nigel Henderson

Research Project Manager: Mr James Cooper

Ethics Ref: 15-LO-2069

IRAS Number: 185760

ClinicalTrials.gov ID: NCT0251901

NIHR Number:  PB-PG-1013-32017